These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7637204)

  • 1. [General pharmacology of T-3761, a new oral quinolone antibacterial agent (1). Effect on the central nervous system].
    Furuhata K; Hiraiwa T; Ono S; Tanaka K; Shimotori T; Makino S; Kitamura K; Aikawa Y; Izumi Y; Kimura T
    Jpn J Antibiot; 1995 May; 48(5):692-705. PubMed ID: 7637204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [General pharmacology of T-3761, a new oral quinolone antibacterial agent (2). Effect on the respiratory and cardiovascular systems, autonomic nervous system and other functions].
    Furuhata K; Hiraiwa T; Terashima N; Arai H; Ono S; Hashiba K; Maekawa M; Kitamura K; Nakada Y; Mori Y
    Jpn J Antibiot; 1995 May; 48(5):706-32. PubMed ID: 7637205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].
    Fukuda H; Kawamura Y
    Jpn J Antibiot; 2002 Jun; 55(3):270-80. PubMed ID: 12199111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [General pharmacology of T-3262, a new pyridonecarboxylic acid].
    Hirai S; Hiraiwa T; Arai H; Ono S; Tanaka K; Hashiba K; Nakada Y; Goden K; Tanada K; Maekawa M
    Jpn J Antibiot; 1989 Apr; 42(4):831-53. PubMed ID: 2769937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system.
    Nakamura T; Fukuda H; Morita Y; Soumi K; Kawamura Y
    J Toxicol Sci; 2003 Feb; 28(1):35-45. PubMed ID: 12696183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
    Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
    Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
    Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T
    Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G; Morimoto S; Shiomi M
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacology of the new quinolone antibacterial agent levofloxacin.
    Takasuna K; Kasai Y; Usui C; Takahashi M; Hirohashi M; Tamura K; Takayama S
    Arzneimittelforschung; 1992 Mar; 43(3A):408-18. PubMed ID: 1622443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
    Shintani S; Toba Y; Suzuki S; Ninomiya S; Umezato M; Hiyama T
    Arzneimittelforschung; 1985; 35(7A):1157-62. PubMed ID: 4074429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [General pharmacology of T-1982, a new cephamycin antibiotic].
    Takai A; Hirai S; Watanabe I; Hiraiwa T; Abe N; Arai H; Omori M; Tanada K; Senda N; Hashiba K; Matsukura K; Takata K; Okami H
    Jpn J Antibiot; 1982 Sep; 35(9):2139-54. PubMed ID: 7143714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
    Matsuno Y; Hori H; Oka M; Nakamura H; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):62-8. PubMed ID: 3513778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of GABAA receptor inhibition required for quinolone-induced convulsions in mice.
    Tsutomi Y; Matsubayashi K; Akahane K
    J Antimicrob Chemother; 1994 Nov; 34(5):737-46. PubMed ID: 7706169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
    Murata T; Sakaya S; Hoshino T; Umetsu T; Hirano T; Nishio S
    Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological properties of a new fluoroquinolone on the central nervous system in rodents.
    Guiol C; Ledoussal C; Surgé JM
    Arzneimittelforschung; 1993 Jan; 43(1):56-60. PubMed ID: 8447850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [General pharmacology of T-2588, a new oral cephem antibiotic].
    Hirai S; Kodama T; Hiraiwa T; Abe N; Arai H; Ono S; Omori M; Nakada Y; Hashiba K; Tanada K
    Jpn J Antibiot; 1986 Apr; 39(4):958-78. PubMed ID: 3761550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Single administration toxicity studies of T-3761 in mice, rats and dogs].
    Nakagawa S; Iwai N; Komae N; Nagasawa M; Kawamura Y; Kodama T
    Jpn J Antibiot; 1995 Jun; 48(6):754-68. PubMed ID: 7666580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.